Understanding the Science Behind the Treatment
The combination of 5-fluorouracil (5-FU) and calcipotriene has attracted attention because it works differently from traditional approaches to treating actinic keratosis. This page explains the science behind the combination in straightforward language, helping you understand what researchers discovered, how the treatment works, and what published clinical studies have shown.
Understanding Actinic Keratosis
Actinic keratosis (AK) develops after years of cumulative sun exposure and is one of the most common conditions treated by dermatologists. These rough, scaly patches are considered precancerous because some may progress to squamous cell carcinoma if left untreated. While not every AK becomes cancerous, treating damaged skin early is an important part of skin cancer prevention.45
Why Current Treatments Can Be Challenging
Several effective treatments are available for actinic keratosis, including topical field therapies that treat both visible and invisible sun damage. Some treatment regimens, however, require several weeks of application and may cause redness, irritation, crusting, and discomfort that can make completing therapy challenging for some patients. Researchers wanted to explore whether activating the immune system alongside traditional therapy could produce a strong clinical response using a much shorter treatment regimen.
The Scientific Discovery
Researchers at Washington University discovered that calcipotriene, a vitamin D derivative commonly used to treat psoriasis, can help activate the skin’s immune response. When combined with 5-FU, researchers observed an immune response directed toward sun-damaged skin cells. Rather than relying only on the effects of chemotherapy, the combination appears to help the immune system recognize and eliminate damaged cells more effectively.1
What to Expect During Treatment
Most participants experienced redness and inflammation during treatment. Although these skin reactions can appear dramatic, they are expected and reflect the immune response observed in the clinical study. In the published trial, redness generally peaked approximately 10 to 11 days after treatment before gradually resolving. Researchers did not report serious treatment-related complications such as scarring, infection, or systemic side effects.1